ストックスクリーナーアプリを入手
2.10
0.00%
0.00
アフターアワーズ：
2.11
0.010
+0.48%
前日終値:
$2.10
開ける：
$2.14
24時間の取引高:
149.26K
Relative Volume:
0.44
時価総額：
$133.83M
収益：
-
当期純損益:
$-30.92M
株価収益率:
-3.4832
EPS:
-0.6029
ネットキャッシュフロー:
$-27.39M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+2.94%
6か月 パフォーマンス:
+5.53%
1年 パフォーマンス:
-14.29%
1日の値動き範囲:
$2.045
$2.15
1週間の範囲:
$2.03
$2.22
52週間の値動き範囲:
$0.41
$3.43
Tuhura Biosciences Inc Stock (HURA) Company Profile
名前
Tuhura Biosciences Inc
セクター
電話
813-875-6600
住所
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
2.10 | 133.83M | 0 | -30.92M | -27.39M | -0.6029 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-27 | 開始されました | Citizens | Mkt Outperform |
| 2025-03-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-19 | 開始されました | Rodman & Renshaw | Buy |
| 2024-11-05 | 開始されました | Maxim Group | Buy |
Tuhura Biosciences Inc (HURA) 最新ニュース
TuHURA Biosciences Draws Additional Funds From Credit Facility - TipRanks
Citizens reiterates TuHURA Biosciences stock rating on AML therapy progress - Investing.com India
TuHURA Biosciences Inc (NASDAQ: HURA) Share Price, HURA Stock News, HURA Share Price & Updates - kalkine.com.au
TuHURA Biosciences Expands Use of Revolving Credit Facility - TipRanks
TuHURA Biosciences Adopts 2026 Inducement Equity Plan - TipRanks
TuHURA receives FDA clearance for leukemia drug trial - Investing.com
TuHURA Biosciences Receives FDA Clearance for TBS-2025 - Intellectia AI
A cancer drug company CEO will speak in New York on Sept. 14 - Stock Titan
TuHURA Biosciences (HURA) Slips 0.93% as Stock Tests Key Technical LevelsNAAIM Leverage - dars.gov.et
TuHURA Biosciences to Present at Investment Conference - Intellectia AI
TuHURA Biosciences draws additional funds from credit facility - TipRanks
TuHURA Biosciences, Inc.Common Stock (HURA) Stock Price, News, Quote & History - FinancialContent
TuHURA (HURA) Q2 2026 Earnings: Reported EPS Tops Expectations; After Earnings: Shares Finish 5.12% Lower in the Available RecordQuarterly Earnings Report - dars.gov.et
TuHURA Biosciences | 8-K: Current report - Moomoo
H.C. Wainwright Maintains TuHURA Biosciences(HURA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Form 8K TuHURA Biosciences Inc For: 19 August By Investing.com - Investing.com South Africa
TuHURA (HURA) Technicals: Closes 5.56% Higher at $2.28 in the Latest Session; Boundary Watch: the Supplied Trading Band Runs From $2.17 to $2.39Breakout Confirmation - dars.gov.et
TuHURA Biosciences stockholders approve share issuance, elect directors at annual meeting - Investing.com Canada
HURA: All proposals passed, including director elections and share issuance, with no stockholder questions - TradingView
HURA: All proposals, including director elections and share issuance, were approved without dissent - TradingView
Citizens reiterates TuHURA Biosciences stock rating on pipeline progress By Investing.com - Investing.com South Africa
HURA Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Jump 7.4%Low Estimate Range - vinanet.vn
TuHURA Biosciences Expect Preliminary Results From IR Study IFX-2.0 With Keytruda for Deep Seated MCC in 1H2027 >HURA - Moomoo
TuHURA Biosciences Extends Runway as Immuno-Oncology Pipeline Advances - TipRanks
TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord - MarketBeat
TuHURA Biosciences Q2 Results: EPS beats estimate, losses narrow 33% YoY - scanx.trade
TuHURA Secures $50M Credit Facility Extending Cash Runway into 2028 - Minichart
Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update - TradingView
Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com - Investing.com Nigeria
TuHURA Biosciences (HURA) deepens R&D spend and adds $50M credit facility - Stock Titan
TuHURA Reports $1.0 Million Cash and Advances TBS-2025 AML Program - Quiver Quantitative
TuHURA Bios reports Q2 2026: $1.0M cash, R&D $6.6M, $50M credit facility extends runway - TradingView
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
TuHURA Biosciences (HURA) Earnings Date and Reports 2026 - marketbeat.com
TuHURA at canaccord growth conference: late-stage push gains traction By Investing.com - Investing.com Nigeria
TuHURA at canaccord growth conference: late-stage push gains traction - Investing.com
Enterprise value to EBIT forward of TuHURA Biosciences, Inc. – NASDAQ:HURA - TradingView
HURA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
TuHURA Biosciences (HURA) Expected to Release Quarterly Earnings on Thursday - MarketBeat
TuHURA Biosciences (HURA) Slips 1.38% as Biotech Stock Holds Above Key $2.03 SupportMax Pain Level - careplusvn.com
HURA Q1 2026 Earnings: EPS Miss Widens as Pre-Revenue Oncology Pipeline Drives CostsNew Analyst Coverage - vinanet.vn
HURA Q1 2026 Earnings: EPS Miss With No Revenue and Stock Advance Defies ResultsEarnings Season Review - careplusvn.com
TuHURA Biosciences Expands Revolving Credit Facility Utilization - TipRanks
TuHURA Biosciences (HURA) Slips 3.62% as Shares Test Support Near $2.02Market Leader Picks - careplusvn.com
TuHURA Biosciences Inc (HURA) Cash Flow - TradingKey
Tuhura Biosciences Inc (HURA) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):